| Prev Close | 159.25 |
| Day Low/High | 159.04 / 161.19 |
| 52 Wk Low/High | 114.27 / 197.00 |
| Avg Volume | 4.76M |
Allergan Plc (AGN)
159.11
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 328.03M |
| Market Cap | 51.91B |
| EPS | -15.30 |
| P/E Ratio | N/A |
| Div & Yield | 2.96 (1.85%) |
Latest News
Real Money Post-Industrial Average Leads Major Indexes So Far for Year
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Big Pharma Sees Pockets of Recent Insider Buying
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
Powell's Verbal Fouls, an Equity Beatdown and Silence of the Lam: Market Recon
The Fed chairman's news conference threw markets for a loop with hawkish words that did not support the Fed's dovish actions.
Jim Cramer: Don't Play Earnings Season, Invest in It
Here are my five rules for handling earnings season.
Buyout Speculation Picks Up in Biotech
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
AbbVie Insiders Buying Shares
Stocks see a nice surge on the open on optimism around trade talks resuming between the U.S. and China, although negotiations will be ongoing for many months and no permanent resolution seems on the horizon. The U.S. PMI Manufacturing Index also cam...
Now at the Plate, Your Pinch Hitter, Bret Jensen!
It is good to be sitting in for Doug Kass here on The Daily Diary as we open trading in the second half of 2019. June ended on an up note as all the major indices drifted up last week to close out the month and quarter. The market did an admirable j...
My 3 Predictions for the Second Half of 2019
Watch the Russell 2000, housing activity, and mergers and acquisitions.
AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
I Believe AbbVie and Allergan Need Each Other
With no other bidder expected to emerge, this is a high risk arbitrage play.
Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
AbbVie Is Likely to Decline as Investors Digest Its Takeover Announcement
Let's look closer at the charts and indicators of ABBV.
AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles
AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
Watch These 9 Companies in a Botox Export Boom Out of South Korea
South Korea is the plastic surgery capital of the world. These companies are manufacturing botox strains - but the big business is abroad, if they can crack the China and U.S. markets.
Jim Cramer: These 7 True Laggards Have Caught Fire
These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.
Allergan Stock Slips Despite Beat and Raised Guidance
Shares of the maker of Botox are struggling despite its latest results exceeding expectations.
More Mud on Johnson & Johnson?
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Watching Shares of Och-Ziff Capital Management
With shares breaking above the recent, albeit small, pennant, there might be reason for optimism.
